Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
110 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-08-03
Study Completion Date
2022-08-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117 administered IV and/or SC. Up to 112 healthy, adult male and female subjects of non-childbearing potential will be enrolled in this trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
NCT03457649
Healthy Volunteers
COMPLETED
PHASE1
A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants
NCT05670704
Healthy Volunteers
COMPLETED
PHASE1
Study to Evaluate HT-4253 in Healthy Subjects
NCT06537817
Normal Healthy Subjects
COMPLETED
PHASE1
CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
NCT03335956
Healthy
COMPLETED
PHASE1
SAD and MAD Study of FTX-101 in Healthy Male Subjects
NCT06617546
Healthy Volunteers
TERMINATED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Healthy Volunteers
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
OTHER
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ARGX-117 IV
Subjects receiving ARGX-117 IV
Group Type
EXPERIMENTAL
ARGX-117
Intervention Type
BIOLOGICAL
Subjects treated with ARGX-117
Placebo IV
Subjects receiving placebo IV
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Subjects treated with placebo
ARGX-117 PH20 SC
Subjects receiving ARGX-117 PH20 SC
Group Type
EXPERIMENTAL
ARGX-117 PH20 SC
Intervention Type
BIOLOGICAL
Subjects treated with ARGX-117 PH20 SC
Placebo PH20 SC
Subjects receiving placebo PH20 SC
Group Type
PLACEBO_COMPARATOR
Placebo PH20 SC
Intervention Type
OTHER
Subjects treated with placebo PH20 SC
ARGX-117 + rHuPH20
Subjects receiving ARGX-117 + rHuPH20
Group Type
EXPERIMENTAL
ARGX-117 + rHuPH20
Intervention Type
BIOLOGICAL
Subjects treated with ARGX-117 + rHuPH20
Placebo + rHuPH20
Subjects receiving placebo + rHuPH20
Group Type
PLACEBO_COMPARATOR
placebo + rHuPH20
Intervention Type
OTHER
Subjects treated with placebo + rHuPH20
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARGX-117
Subjects treated with ARGX-117
Intervention Type
BIOLOGICAL
Placebo
Subjects treated with placebo
Intervention Type
OTHER
ARGX-117 + rHuPH20
Subjects treated with ARGX-117 + rHuPH20
Intervention Type
BIOLOGICAL
placebo + rHuPH20
Subjects treated with placebo + rHuPH20
Intervention Type
OTHER
ARGX-117 PH20 SC
Subjects treated with ARGX-117 PH20 SC
Intervention Type
BIOLOGICAL
Placebo PH20 SC
Subjects treated with placebo PH20 SC
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject is between 18 to 65 years of age, inclusive, at the time the informed consent form (ICF) is signed.
2. The subject is either male, or female of nonchildbearing potential. Females in the following categories are considered a woman of nonchildbearing potential:
1. Postmenopausal female: A postmenopausal state is defined as continuous amenorrhea for at least 1 year without an alternative medical cause and a follicle-stimulating hormone (FSH) measurement of \>40 IU/L. A historical pretreatment FSH measurement of\>40 IU/L is accepted as proof of a postmenopausal state for subjects on hormone replacement therapy.
2. Surgically sterile female: women who have had a documented permanent sterilization procedure (ie, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
3. Female subjects must have a negative serum pregnancy test on day -1 before IMP can be administered.
4. The subject has a body mass index (BMI) within the range 18 to 30 kg/m2 and body weight 50 to 100 kg (inclusive) before IMP administration.
5. The subject is able to understand the requirements of the study and provide written informed consent (including consent for the use and disclosure of research-related health information), and is willing and able to comply with the study protocol procedures (including the required study visits).
6. The subject is in good physical and mental health, per the opinion of the investigator, based on medical history; physical examination findings; ECG recordings; vital sign measurements; systemic lupus erythematous (SLE) panel results; and biochemistry, hematology, INR, and urinalysis laboratory test results prior to the first dose of IMP on day 1.
7. Nonsterilized male subjects who are sexually active with a female partner of childbearing potential must use effective contraception from the signing of the ICF through 260 days after the last IMP administration. A male subject practicing true sexual abstinence (as consistent with the preferred and usual lifestyle) can be included. Sterilized male subjects who have had a vasectomy and with documented absence of sperm post-procedure can be included. Male subjects are not allowed to donate sperm from signing of the ICF through 260 days after the last dose of IMP.
8. The subject has abdominal skin that, in the opinion of the investigator, allows for the absorption and localized safety assessment of SC administration (applicable for dose levels with SC administration only).
9. The subject agrees to discontinue and refrain from the use of all medications, including nonprescription and/or prescription medications, for at least 2 weeks before the first dose of IMP through the EOS visit on day 260 (Part A \[SAD\]), day 288 (Part B \[MAD\], cohorts 1 through 5). The occasional use of paracetamol at doses up to 2 g/day with a maximum of 10 g/2 weeks is allowed upon approval from the investigator. COVID-19 immunization recommendations are described in Section 4.3.1.1.
10. The subject is a nonsmoker and does not use any nicotine-containing products. A nonsmoker is defined as an individual who has abstained from smoking for at least 3 months prior to screening.
11. The subject has a negative urine drug and alcohol screen for amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, tricyclic antidepressants and alcohol at screening and on day -1.
12. The subject has a body temperature of 35.5 °C to 37.6 °C at screening and prior to the first dose of IMP day 1.
2. The subject is either male, or female of nonchildbearing potential. Females in the following categories are considered a woman of nonchildbearing potential:
1. Postmenopausal female: A postmenopausal state is defined as continuous amenorrhea for at least 1 year without an alternative medical cause and a follicle-stimulating hormone (FSH) measurement of \>40 IU/L. A historical pretreatment FSH measurement of\>40 IU/L is accepted as proof of a postmenopausal state for subjects on hormone replacement therapy.
2. Surgically sterile female: women who have had a documented permanent sterilization procedure (ie, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
3. Female subjects must have a negative serum pregnancy test on day -1 before IMP can be administered.
4. The subject has a body mass index (BMI) within the range 18 to 30 kg/m2 and body weight 50 to 100 kg (inclusive) before IMP administration.
5. The subject is able to understand the requirements of the study and provide written informed consent (including consent for the use and disclosure of research-related health information), and is willing and able to comply with the study protocol procedures (including the required study visits).
6. The subject is in good physical and mental health, per the opinion of the investigator, based on medical history; physical examination findings; ECG recordings; vital sign measurements; systemic lupus erythematous (SLE) panel results; and biochemistry, hematology, INR, and urinalysis laboratory test results prior to the first dose of IMP on day 1.
7. Nonsterilized male subjects who are sexually active with a female partner of childbearing potential must use effective contraception from the signing of the ICF through 260 days after the last IMP administration. A male subject practicing true sexual abstinence (as consistent with the preferred and usual lifestyle) can be included. Sterilized male subjects who have had a vasectomy and with documented absence of sperm post-procedure can be included. Male subjects are not allowed to donate sperm from signing of the ICF through 260 days after the last dose of IMP.
8. The subject has abdominal skin that, in the opinion of the investigator, allows for the absorption and localized safety assessment of SC administration (applicable for dose levels with SC administration only).
9. The subject agrees to discontinue and refrain from the use of all medications, including nonprescription and/or prescription medications, for at least 2 weeks before the first dose of IMP through the EOS visit on day 260 (Part A \[SAD\]), day 288 (Part B \[MAD\], cohorts 1 through 5). The occasional use of paracetamol at doses up to 2 g/day with a maximum of 10 g/2 weeks is allowed upon approval from the investigator. COVID-19 immunization recommendations are described in Section 4.3.1.1.
10. The subject is a nonsmoker and does not use any nicotine-containing products. A nonsmoker is defined as an individual who has abstained from smoking for at least 3 months prior to screening.
11. The subject has a negative urine drug and alcohol screen for amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, tricyclic antidepressants and alcohol at screening and on day -1.
12. The subject has a body temperature of 35.5 °C to 37.6 °C at screening and prior to the first dose of IMP day 1.
Exclusion Criteria
1. The subject has a known hypersensitivity to any of the components of the IMP, or, in the opinion of the investigator, a history of a significant allergic reaction to any drug.
2. The subject has previously participated in a clinical study with efgartigimod and was administered an IMP.
3. The subject has a positive serum test at screening for an active viral infection with any of the following conditions:
1. Hepatitis B virus (HBV) that is indicative of an acute or chronic infection (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf)
2. Hepatitis C virus (HCV) based on HCV antibody assay
3. Human immunodeficiency virus
4. The subject tests positively at screening for SLE as determined by the SLE test panel.
5. The subject has a known family history of SLE.
6. The subject has known clinically relevant immunological disorders.
7. The subject has a history of severe allergic or anaphylactic reactions.
8. The subject has clinical evidence of significant serious diseases, underwent a recent major surgery, or has any other condition that, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk. The conditions and diseases that will lead to subject exclusion include recognized uncontrolled risk factors associated with acute respiratory distress syndrome (ARDS) and death in subjects with COVID-19 (eg, hypertension, diabetes, asthma, or chronic obstructive pulmonary disease \[COPD\]).
9. The subject has a clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening.
10. The subject has the presence or sequelae of gastrointestinal, liver, kidney, or other conditions known to potentially interfere with the absorption, distribution, metabolism, or excretion of IMP.
11. The subject has an estimated glomerular filtration rate of \<80 mL/min/1.73 m² (calculated per the Chronic Kidney Disease Epidemiology Collaboration method) at screening.
12. The subject has a history of malignancy except for:
1. Adequately treated basal cell or squamous cell skin cancer
2. Carcinoma in situ of the cervix
13. The subject has known genetic deficiencies for the complement cascade system.
14. The subject has clinically relevant abnormalities detected on an ECG that are related to either rhythm or conduction (eg, QTcF \>450 ms for male and QTcF \>470 ms for female subjects, or a known long QT syndrome).
15. The subject has clinically relevant vital sign abnormalities before the first dose of IMP.
16. The subject had significant blood loss, including blood donation \>500 mL, or transfusion of any blood product within 12 weeks before the first dose of IMP, or the subject has a scheduled transfusion within 4 weeks after the end of the study.
17. The subject has received treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months before the first dose of IMP.
18. The subject has a history of any of the following:
1. consuming more than 21 units of alcoholic beverages per week (Note: 1 unit is 330 mL of beer, 110 mL of wine, or 28 mL of spirits)
2. alcoholism or drug, chemical, substance abuse within 2 years before screening
3. consuming a large quantity (\>6 cups per day) of coffee, tea, or the equivalent in the 4 weeks before the first dose of IMP.
19. The subject is concurrently participating or has participated, within 90 days before the first dose of IMP or, if known, 5 half-lives of the investigational drug (whichever is longer), in any drug/device or biologic investigational research study.
20. The subject has been administered any systemic immunosuppressant agent within 6 months prior to the first dose of IMP.
21. The subject has been administered any systemic steroid within 3 months prior to the first dose of IMP.
22. The subject is an investigator, subinvestigator, research assistant, pharmacist, study coordinator, or other staff or relative of study personnel directly involved with the conduct of the study.
23. The subject has any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
24. The subject is a pregnant or lactating female, or intends to become pregnant during the study or within 260 days after the last dose of IMP.
25. The subject has any condition that impairs phlebotomy.
26. The subject has a positive nasopharyngeal polymerase chain reaction (PCR) test for SARS-CoV-2 on day -2 or -1.
27. The subject has any contact with anyone who has tested positive for SARS-CoV-2 or COVID-19 within the last 2 weeks prior to admission to the clinical research center.
2. The subject has previously participated in a clinical study with efgartigimod and was administered an IMP.
3. The subject has a positive serum test at screening for an active viral infection with any of the following conditions:
1. Hepatitis B virus (HBV) that is indicative of an acute or chronic infection (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf)
2. Hepatitis C virus (HCV) based on HCV antibody assay
3. Human immunodeficiency virus
4. The subject tests positively at screening for SLE as determined by the SLE test panel.
5. The subject has a known family history of SLE.
6. The subject has known clinically relevant immunological disorders.
7. The subject has a history of severe allergic or anaphylactic reactions.
8. The subject has clinical evidence of significant serious diseases, underwent a recent major surgery, or has any other condition that, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk. The conditions and diseases that will lead to subject exclusion include recognized uncontrolled risk factors associated with acute respiratory distress syndrome (ARDS) and death in subjects with COVID-19 (eg, hypertension, diabetes, asthma, or chronic obstructive pulmonary disease \[COPD\]).
9. The subject has a clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening.
10. The subject has the presence or sequelae of gastrointestinal, liver, kidney, or other conditions known to potentially interfere with the absorption, distribution, metabolism, or excretion of IMP.
11. The subject has an estimated glomerular filtration rate of \<80 mL/min/1.73 m² (calculated per the Chronic Kidney Disease Epidemiology Collaboration method) at screening.
12. The subject has a history of malignancy except for:
1. Adequately treated basal cell or squamous cell skin cancer
2. Carcinoma in situ of the cervix
13. The subject has known genetic deficiencies for the complement cascade system.
14. The subject has clinically relevant abnormalities detected on an ECG that are related to either rhythm or conduction (eg, QTcF \>450 ms for male and QTcF \>470 ms for female subjects, or a known long QT syndrome).
15. The subject has clinically relevant vital sign abnormalities before the first dose of IMP.
16. The subject had significant blood loss, including blood donation \>500 mL, or transfusion of any blood product within 12 weeks before the first dose of IMP, or the subject has a scheduled transfusion within 4 weeks after the end of the study.
17. The subject has received treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months before the first dose of IMP.
18. The subject has a history of any of the following:
1. consuming more than 21 units of alcoholic beverages per week (Note: 1 unit is 330 mL of beer, 110 mL of wine, or 28 mL of spirits)
2. alcoholism or drug, chemical, substance abuse within 2 years before screening
3. consuming a large quantity (\>6 cups per day) of coffee, tea, or the equivalent in the 4 weeks before the first dose of IMP.
19. The subject is concurrently participating or has participated, within 90 days before the first dose of IMP or, if known, 5 half-lives of the investigational drug (whichever is longer), in any drug/device or biologic investigational research study.
20. The subject has been administered any systemic immunosuppressant agent within 6 months prior to the first dose of IMP.
21. The subject has been administered any systemic steroid within 3 months prior to the first dose of IMP.
22. The subject is an investigator, subinvestigator, research assistant, pharmacist, study coordinator, or other staff or relative of study personnel directly involved with the conduct of the study.
23. The subject has any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
24. The subject is a pregnant or lactating female, or intends to become pregnant during the study or within 260 days after the last dose of IMP.
25. The subject has any condition that impairs phlebotomy.
26. The subject has a positive nasopharyngeal polymerase chain reaction (PCR) test for SARS-CoV-2 on day -2 or -1.
27. The subject has any contact with anyone who has tested positive for SARS-CoV-2 or COVID-19 within the last 2 weeks prior to admission to the clinical research center.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
argenx
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigator Site 1
Groningen, , Netherlands
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Netherlands
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARGX-117-1901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects
NCT07126704
NOT_YET_RECRUITING
PHASE1
A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004
NCT04277910
COMPLETED
PHASE1
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
NCT05195723
COMPLETED
PHASE1
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
NCT02657122
COMPLETED
PHASE1
Study of Orally Administered BEBT-503 in Healthy Subjects
NCT05391880
COMPLETED
PHASE1
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants
NCT03676322
COMPLETED
PHASE1
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
NCT06968338
RECRUITING
PHASE1
SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects
NCT05476107
COMPLETED
PHASE1
A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects
NCT05948774
COMPLETED
PHASE1
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
NCT03334084
COMPLETED
PHASE1
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
NCT02955459
COMPLETED
PHASE1
AZD6423 SAD/MAD Study in Healthy Volunteers
NCT01926366
COMPLETED
PHASE1
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
NCT04243863
COMPLETED
PHASE1
A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects
NCT06744868
COMPLETED
PHASE1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers
NCT01173770
COMPLETED
PHASE1
Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023
NCT03542435
COMPLETED
PHASE1
The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects
NCT04880512
UNKNOWN
PHASE1
CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
NCT03508635
COMPLETED
PHASE1
A First-in-Human Study of AV-001 in Healthy Subjects
NCT04737486
COMPLETED
PHASE1
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
NCT01872065
COMPLETED
PHASE1
A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers
NCT01209221
COMPLETED
PHASE1
Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects
NCT06995001
COMPLETED
PHASE1
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
NCT06453824
COMPLETED
PHASE1
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
NCT05756920
COMPLETED
PHASE1
A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects
NCT01284036
COMPLETED
PHASE1